These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 21444233)

  • 21. Folate Supplementation for Methotrexate Therapy in Patients With Rheumatoid Arthritis: A Systematic Review.
    Liu L; Liu S; Wang C; Guan W; Zhang Y; Hu W; Zhang L; He Y; Lu J; Li T; Liu X; Xuan Y; Wang P
    J Clin Rheumatol; 2019 Aug; 25(5):197-202. PubMed ID: 29975207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subcutaneous administration of methotrexate at high doses makes a better performance in the treatment of rheumatoid arthritis compared with oral administration of methotrexate: A systematic review and meta-analysis.
    Li D; Yang Z; Kang P; Xie X
    Semin Arthritis Rheum; 2016 Jun; 45(6):656-62. PubMed ID: 26686022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.
    Kremer JM; Cohen S; Wilkinson BE; Connell CA; French JL; Gomez-Reino J; Gruben D; Kanik KS; Krishnaswami S; Pascual-Ramos V; Wallenstein G; Zwillich SH
    Arthritis Rheum; 2012 Apr; 64(4):970-81. PubMed ID: 22006202
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Why we recommend parenteral methotrexate for the treatment of rheumatoid arthritis: a response and overview of the literature].
    Fiehn C;
    Z Rheumatol; 2019 May; 78(4):385-387. PubMed ID: 30941504
    [No Abstract]   [Full Text] [Related]  

  • 25. Outcomes related to methotrexate dose and route of administration in patients with rheumatoid arthritis: a systematic literature review.
    Goodman SM; Cronstein BN; Bykerk VP
    Clin Exp Rheumatol; 2015; 33(2):272-8. PubMed ID: 25536122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative efficacy of subcutaneous versus oral methotrexate in active rheumatoid arthritis.
    Islam MS; Haq SA; Islam MN; Azad AK; Islam MA; Barua R; Hasan MM; Mahmood M; Safiuddin M; Rahman MM; Osmany MF; Bari N; Rumki RS; Rashid FB
    Mymensingh Med J; 2013 Jul; 22(3):483-8. PubMed ID: 23982537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate.
    Harley CR; Frytak JR; Tandon N
    Am J Manag Care; 2003 Oct; 9(6 Suppl):S136-43. PubMed ID: 14577718
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inadequate response or intolerability to oral methotrexate: Is it optimal to switch to subcutaneous methotrexate prior to considering therapy with biologics?
    Yadlapati S; Efthimiou P
    Rheumatol Int; 2016 May; 36(5):627-33. PubMed ID: 26936262
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort.
    Müller RB; von Kempis J; Haile SR; Schiff MH
    Semin Arthritis Rheum; 2015 Aug; 45(1):28-34. PubMed ID: 25895697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Methotrexate: mainstay of rheumatoid arthritis treatment].
    Jacobs JW; Bijlsma JW
    Ned Tijdschr Geneeskd; 2009; 153():A879. PubMed ID: 19785862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.
    Smolen JS; Nash P; Durez P; Hall S; Ilivanova E; Irazoque-Palazuelos F; Miranda P; Park MC; Pavelka K; Pedersen R; Szumski A; Hammond C; Koenig AS; Vlahos B
    Lancet; 2013 Mar; 381(9870):918-29. PubMed ID: 23332236
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis).
    Colebatch AN; Marks JL; Edwards CJ
    Cochrane Database Syst Rev; 2011 Nov; (11):CD008872. PubMed ID: 22071858
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial).
    Verstappen SM; Jacobs JW; van der Veen MJ; Heurkens AH; Schenk Y; ter Borg EJ; Blaauw AA; Bijlsma JW;
    Ann Rheum Dis; 2007 Nov; 66(11):1443-9. PubMed ID: 17519278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methotrexate Dosage Reduction Upon Adalimumab Initiation: Clinical and Ultrasonographic Outcomes from the Randomized Noninferiority MUSICA Trial.
    Kaeley GS; Evangelisto AM; Nishio MJ; Goss SL; Liu S; Kalabic J; Kupper H
    J Rheumatol; 2016 Aug; 43(8):1480-9. PubMed ID: 27307526
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimal methotrexate dose is associated with better clinical outcomes than non-optimal dose in daily practice: results from the ESPOIR early arthritis cohort.
    Gaujoux-Viala C; Rincheval N; Dougados M; Combe B; Fautrel B
    Ann Rheum Dis; 2017 Dec; 76(12):2054-2060. PubMed ID: 28866645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial.
    Braun J; Kästner P; Flaxenberg P; Währisch J; Hanke P; Demary W; von Hinüber U; Rockwitz K; Heitz W; Pichlmeier U; Guimbal-Schmolck C; Brandt A;
    Arthritis Rheum; 2008 Jan; 58(1):73-81. PubMed ID: 18163521
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.
    Smolen JS; Pangan AL; Emery P; Rigby W; Tanaka Y; Vargas JI; Zhang Y; Damjanov N; Friedman A; Othman AA; Camp HS; Cohen S
    Lancet; 2019 Jun; 393(10188):2303-2311. PubMed ID: 31130260
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dosage and mode of administration of methotrexate in clinical trials: comment on the article by Genovese et al.
    Seitz M; Villiger PM
    Arthritis Rheum; 2003 Mar; 48(3):863. PubMed ID: 12632454
    [No Abstract]   [Full Text] [Related]  

  • 39. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis.
    Bannwarth B; Péhourcq F; Schaeverbeke T; Dehais J
    Clin Pharmacokinet; 1996 Mar; 30(3):194-210. PubMed ID: 8882301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.